Tag: Pembrolizumab
-
Genmab’s Petosemtamab–Keytruda Combination Improves Survival in Phase 3 Head and Neck Cancer Trial
Genmab’s petosemtamab plus Keytruda improved survival in Phase 3 head and neck cancer testing. A closer look at the findings and their meaning for patients.
-
Moderna’s Personalized mRNA Cancer Therapy Delivers First Phase 3 Win
Moderna and Merck’s personalized mRNA cancer therapy intismeran met both recurrence-free survival and distant metastasis-free survival endpoints in Phase 3 melanoma, marking a major milestone for individualized mRNA-based cancer treatment.